ReLiFiRa (Real Life Filgotinib in Rheumatoid Arthritis): Retrospective Study of Efficacy and Safety in Common Clinical Practice

ReLiFiRa (Real Life Filgotinib in Rheumatoid Arthritis): Retrospective Study of Efficacy and Safety in Common Clinical Practice

Background: Filgotinib (FIL) is a selective JAK1 inhibitor with an affinity 30-fold higher than JAK2, approved to treat moderate to severe active rheumatoid arthritis (RA), in adults with inadequate response or intolerance to one or more disease-modifying antirheumatic drugs (DMARDs). Methods: We co...

Full description

Bibliographic Details
Main Authors:	Maurizio Benucci, Marco Bardelli, Massimiliano Cazzato, Elenia Laurino, Francesca Bartoli, Arianna Damiani, Francesca Li Gobbi, Anna Panaccione, Luca Di Cato, Laura Niccoli, Bruno Frediani, Marta Mosca, Serena Guiducci, Fabrizio Cantini
Format:	Article
Language:	English
Published:	MDPI AG 2023-08-01
Series:	Journal of Personalized Medicine
Subjects:	rheumatoid arthritis filgotinib real-life
Online Access:	https://www.mdpi.com/2075-4426/13/9/1303

Similar Items

Different Biomarkers of Response to Treatment with Selective Jak-1 Inhibitors in Rheumatoid Arthritis
by: Maurizio Benucci, et al.
Published: (2023-08-01)

Benefit of Filgotinib, a JAK1 Preferential Inhibitor, in Rheumatoid Arthritis Patients with Previous Rapid Radiographic Progression: Post Hoc Analysis of Two Trials
by: Yoshiya Tanaka, et al.
Published: (2022-11-01)

Cardiovascular safety, cancer and Jak-inhibitors: Differences to be highlighted
by: Maurizio Benucci, et al.
Published: (2022-09-01)

Critical Appraisal of Filgotinib in the Treatment of Ulcerative Colitis: Current Evidence and Place in Therapy
by: Dal Buono A, et al.
Published: (2022-07-01)

Effect of Filgotinib on Body Mass Index (BMI) and Effect of Baseline BMI on the Efficacy and Safety of Filgotinib in Rheumatoid Arthritis
by: Alejandro Balsa, et al.
Published: (2023-09-01)

Geographic Analysis of the Safety and Efficacy of Filgotinib in Rheumatoid Arthritis
by: Bernard Combe, et al.
Published: (2022-10-01)

Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 Study
by: Bernard G. Combe, et al.
Published: (2022-10-01)

Prevention of Radiographic Progression in Higher-Risk Patients with Rheumatoid Arthritis Using Filgotinib in Phase III Studies: Narrative Review of Post Hoc Analyses
by: Yoshiya Tanaka, et al.
Published: (2023-09-01)

Efficacy and safety of filgotinib as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a post-hoc analysis of the phase 2b/3 SELECTION trial
by: Toshifumi Hibi, et al.
Published: (2023-01-01)

Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes
by: Mark Genovese, et al.
Published: (2018-03-01)

Validated DBS method for filgotinib quantitation in rat dried blood spots and its application to a pharmacokinetic study in rats
by: Abhishek Dixit, et al.
Published: (2020-06-01)

Efficacy and safety of selective JAK 1 inhibitor filgotinib in active rheumatoid arthritis patients with inadequate response to methotrexate: comparative study with filgotinib and tocilizumab examined by clinical index as well as musculoskeletal ultrasound assessment (TRANSFORM study): study protocol for a randomized, open-label, parallel-group, multicenter, and non-inferiority clinical trial
by: Toshimasa Shimizu, et al.
Published: (2023-03-01)

Understanding the efficacy of individual Janus kinase inhibitors in the treatment of ulcerative colitis for future positioning in inflammatory bowel disease treatment
by: Hiroshi Nakase
Published: (2023-07-01)

Use of Janus kinase inhibitors in the treatment of immunoinflammatory rheumatic diseases: safety issues
by: B. S. Belov, et al.
Published: (2021-03-01)

Experimental and Investigational Pharmacotherapy for Psoriatic Arthritis: Drugs of the Future
by: Navarini L, et al.
Published: (2020-11-01)

A subgroup analysis of the efficacy of filgotinib for patients with moderately active RA following an inadequate response to methotrexate
by: Buch, MH, et al.
Published: (2021)

Filgotinib for the treatment of rheumatoid arthritis
by: Taylor, P, et al.
Published: (2017)

Therapeutic Potential of Ixekizumab in the Treatment of Ankylosing Spondylitis: A Review on the Emerging Clinical Data
by: Benucci M, et al.
Published: (2020-04-01)

Targeted therapy of inflammatory bowel diseases: realities and prospects
by: I. V. Maev, et al.
Published: (2018-04-01)

Real-Life Comparison of Four JAK Inhibitors in Rheumatoid Arthritis (ELECTRA-<i>i</i> Study)
by: Maurizio Benucci, et al.
Published: (2024-03-01)

Integration with Spilanthes Achmella in fibromyalgia syndrome: open-label study six months after the treatment
by: Marco Bardelli, et al.
Published: (2021-09-01)

Impact of filgotinib on pain control in the phase 3 FINCH studies
by: Taylor, PC, et al.
Published: (2024)

Concomitant use of statins in filgotinib-treated patients with rheumatoid arthritis
by: Taylor, PC, et al.
Published: (2021)

Impact of filgotinib on pain control in the phase 3 FINCH studies
by: Bruno Fautrel, et al.
Published: (2024-02-01)

The Association of uPA, uPAR, and suPAR System with Inflammation and Joint Damage in Rheumatoid Arthritis: suPAR as a Biomarker in the Light of a Personalized Medicine Perspective
by: Maurizio Benucci, et al.
Published: (2022-12-01)

Correction: Impact of filgotinib on pain control in the phase 3 FINCH studies
Published: (2024-04-01)

Predicting Loss of Efficacy after Non-Medical Switching: Correlation between Circulating TNF-α Levels and SB4 in Etanercept to SB4 Switchers and Naïve Patients with Rheumatic Disease
by: Maurizio Benucci, et al.
Published: (2022-07-01)

Correction: Benucci et al. Predicting Loss of Efficacy after Non-Medical Switching: Correlation between Circulating TNF-α Levels and SB4 in Etanercept to SB4 Switchers and Naïve Patients with Rheumatic Disease. <i>J. Pers. Med.</i> 2022, <i>12</i>, 1174
by: Maurizio Benucci, et al.
Published: (2023-01-01)

Personalization of biologic therapy in patients with rheumatoid arthritis: less frequently accounted choice-driving variables
by: Niccoli L, et al.
Published: (2018-10-01)

Efficacy and safety of filgotinib in patients with moderately active rheumatoid arthritis and an inadequate response to methotrexate
by: Buch, MH, et al.
Published: (2024)

Whole blood transcriptional changes following selective inhibition of janus kinase 1 (JAK1) by filgotinib in MTX-naive adults with moderately-to-severely active rheumatoid arthritis (RA) (FINCH3)
by: Taylor, PC, et al.
Published: (2020)

Effect of filgotinib on pain in patients with rheumatoid arthritis: results from phase 3 clinical trials
by: Pope, J, et al.
Published: (2021)

Focus on biosimilar etanercept – bioequivalence and interchangeability
by: Cantini F, et al.
Published: (2018-08-01)

Baricitinib, tofacitinib, upadacitinib, filgotinib, and cytokine signaling in human leukocyte subpopulations: an updated ex-vivo comparison
by: McInnes, IB, et al.
Published: (2020)

Effects of the jak1-selective inhibitor filgotinib on gene expression profile in blood of patients with active rheumatoid
by: Taylor, P, et al.
Published: (2018)

Long-Term Safety, Efficacy, and Patient-Centered Outcomes of Filgotinib in the Treatment of Rheumatoid Arthritis: Current Perspectives
by: Tanaka Y, et al.
Published: (2023-10-01)

Patients with high baseline neutrophil-to-lymphocyte ratio exhibit better response to filgotinib as treatment for rheumatoid arthritis
by: Taylor, PC, et al.
Published: (2024)

Pharmacodynamic effects of filgotinib treatment driving clinical improvement in patients with active psoriatic arthritis enrolled in the EQUATOR trial
by: Dafna Gladman, et al.
Published: (2023-10-01)

Switching from originator adalimumab to biosimilar SB5 in a rheumatology cohort: persistence on treatment, predictors of drug interruption and safety analysis
by: Cosimo Bruni, et al.
Published: (2021-07-01)

Effect of filgotinib on health-related quality of life in active psoriatic arthritis: a randomized phase 2 trial (EQUATOR)
by: Orbai, A-M, et al.
Published: (2019)